Expression levels of hsa-miR-139-3p-4395424, hsa-miR-675-4395192 and hsa-miR-335*-4395296 in normal, benign and malignant adrenocortical lesions
| miRNA | Normal tissue (n=5) | Adenomas (n=9) | Carcinomas (n=4) | Metastasis (n=3) | |||||||||||||||||
| Conn | Cushing | ||||||||||||||||||||
| hsa-miR-139-3p-4395424 | 7.0 | 7.6 | 7.3 | 7.3 | 6.4 | 8.1 | 6.0 | 6.7 | 7.1 | 6.8 | 5.6 | 8.0 | 6.3 | 4.3 | 9.7 | 10.8 | 9.7 | 10.6 | 9.8 | 11.3 | 7.3* |
| hsa-miR-675-4395192 | 6.7 | 5.9 | 6.8 | 5.8 | 5.8 | 8.8 | 6.0 | 7.8 | 6.4 | 6.3 | 5.8 | 5.0 | 7.1 | 4.3 | 10.8 | 11.6 | 10.1 | 10.5 | 10.5 | 10.2 | 7.5* |
| hsa-miR-335*-4395296 | 5.2 | 5.1 | 4.3 | 5.6 | 5.1 | 6.1 | 5.4 | 5.8 | 5.6 | 4.6 | 5.3 | 5.4 | 4.9 | 3.4 | 6.9 | 7.7 | 7.1 | 8.0 | 7.8 | 10.2 | 5.6* |
Data presented in ∆CT of relative threshold cycles indicating fold changes over normal adrenal tissue. Low values indicate high levels of miRNA. Data derived from quantitative reverse transcriptase PCR validation of miRNAs.
↵* miRNA expression levels of this case was beyond the expected range. The amplification curves suggest an insufficient RNU48 control. However, data was not deleted from statistics.